CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA.
Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 12, 2025, at 4:00pm ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical’s Investor Relations website at https://apyxmedical.com/investor_relations/.
About Apyx Medical Corporation
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and now the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$4.03 |
| Daily Change: | 0.13 3.33 |
| Daily Volume: | 123,673 |
| Market Cap: | US$152.410M |
November 17, 2025 November 06, 2025 October 13, 2025 September 29, 2025 August 07, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load